Announcements Trials
Browse Landscape

Phase

Phase 2 28Phase 1/2 11Phase 1 11Phase 3 7Phase NA 1Phase EARLY_PHASE1 1Phase 4 1

Status

Recruiting 2Not yet recruiting 2Active not recruiting 2Completed 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 7

Conditions

Prostatic Neoplasms 4Prostatic Diseases 1Prostate Cancer Metastatic 1Kidney Neoplasms 1Genital Diseases, Male 1Carcinoma, Renal Cell 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 3 × Pluvicto × Clear all
NCT04720157 2026-05-27

PSMAddition

Novartis

Phase 3 Active not recruiting
1,140 enrolled
Genitourinary

Prostatic Neoplasms

NCT04689828 2026-03-23

PSMAfore

Novartis

Phase 3 Active not recruiting
469 enrolled 11 charts 1 FDA
Genitourinary

Prostatic Neoplasms

NCT06959433 2026-02-27

Lu-177 PSMA Treatment in Cell Renal Carcinoma

Ankara University

Phase 3 Not yet recruiting
20 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT07200830 2025-10-01

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Alliance for Clinical Trials in Oncology

Phase 3 Not yet recruiting
1,524 enrolled
Genitourinary

Prostatic Neoplasms

NCT06320067 2025-09-26

STAMPEDE2

University College, London

Phase 3 Recruiting
3,360 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT03511664 2025-01-13

VISION

Endocyte

Phase 3 Completed
861 enrolled 39 charts 1 FDA
Genitourinary

Prostatic Neoplasms

NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER

Phase 3 Recruiting
500 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡